 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 February 2003 | Volume 138 Issue 3 | Pages 197-207
Because of shared routes of transmission, hepatitis C virus (HCV) infection is common in HIV-infected persons, who have been experiencing increasing HCV-related morbidity and mortality since the advent of effective antiretroviral therapy. Infection with HIV appears to adversely affect the outcome of hepatitis C, leading to increased viral persistence after acute infection, higher levels of viremia, and accelerated progression of HCV-related liver disease. In addition, hepatitis C may affect the course and management of HIV infection. The medical management of hepatitis C in HIV-infected persons is complicated by immune suppression, potential drug interactions and toxicities, and other forms of liver disease. In addition, there is little published experience with the safety and efficacy of the best available anti-HCV medications in HIV-infected persons. Thus, current efforts must be directed at preventing HCV and HIV infections and applying the principles learned in treating persons with either infection to manage those with both. Future efforts should include studies of the pathogenesis of HCV infection in HIV-infected persons and large, prospective studies that demonstrate the optimal management of persons co-infected with HIV and HCV. Such efforts will help to eliminate HCV-related liver disease as an emerging threat to HIV-infected persons.
Author and Article Information
From Johns Hopkins University School of Medicine, Baltimore, Maryland.
Grant Support: In part by the National Institute on Injection Drug Abuse (DA-011602, DA-16078, and DA-13806).
Requests for Single Reprints: David L. Thomas, MD, MPH, Division of Infectious Diseases, Johns Hopkins University School of Medicine, 424 Bond Street, Baltimore, MD 21231; e-mail, dthomas{at}jhmi.edu.
Current Author Addresses: Dr. Sulkowski: Division of Infections Diseases, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 448, Baltimore, MD 21287-0003.
Dr. Thomas: Division of Infectious Diseases, Johns Hopkins University School of Medicine, 424 Bond Street, Baltimore, MD 21231. REVIEW
Hepatitis C in the HIV-Infected Person
This article has been cited by other articles:
|
|
 |
|
  L. Sheard and C. Tompkins Contradictions and Misperceptions: An Exploration of Injecting Practice, Cleanliness, Risk, and Partnership in the Lives of Women Drug Users Qual Health Res, November 1, 2008; 18(11): 1536 - 1547. [Abstract] [PDF]
|
|
|
|
 |
|
 C M Wilcox and M S Saag Gastrointestinal complications of HIV infection: changing priorities in the HAART era Gut, June 1, 2008; 57(6): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ebinuma, N. Nakamoto, Y. Li, D. A. Price, E. Gostick, B. L. Levine, J. Tobias, W. W. Kwok, and K.-M. Chang Identification and In Vitro Expansion of Functional Antigen-Specific CD25+ FoxP3+ Regulatory T Cells in Hepatitis C Virus Infection J. Virol., May 15, 2008; 82(10): 5043 - 5053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Schackman, P. A. Teixeira, G. Weitzman, A. I. Mushlin, and I. M. Jacobson Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree? Med Decis Making, April 1, 2008; 28(2): 233 - 242. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Rivero, J. A. Mira, and J. A. Pineda Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors J. Antimicrob. Chemother., March 1, 2007; 59(3): 342 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Verma HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction? J. Antimicrob. Chemother., September 1, 2006; 58(3): 496 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Data Collection on Adverse Events of Anti-HIV Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study. Arch Intern Med, August 14, 2006; 166(15): 1632 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. JITTIWUTIKARN, S. THONGSAWAT, V. SURIYANON, N. MANEEKARN, D. CELENTANO, M. H. RAZAK, N. SRIRAK, T. VONGCHAK, S. KAWICHAI, D. THOMAS, et al. HEPATITIS C INFECTION AMONG DRUG USERS IN NORTHERN THAILAND Am J Trop Med Hyg, June 1, 2006; 74(6): 1111 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Soriano, P. Barreiro, and M. Nunez Management of chronic hepatitis B and C in HIV-coinfected patients J. Antimicrob. Chemother., May 1, 2006; 57(5): 815 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Mistler, M. F. Brunette, B. J. Marsh, R. M. Vidaver, R. Luckoor, and S. D. Rosenberg Hepatitis C treatment for people with severe mental illness. Psychosomatics, March 1, 2006; 47(2): 93 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A Hughes and S. D Shafran Treatment of Hepatitis C in HIV-Coinfected Patients Ann. Pharmacother., March 1, 2006; 40(3): 479 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. McNelis Management of Hepatitis C Infection in the HIV-Infected Patient Journal of Pharmacy Practice, February 1, 2006; 19(1): 37 - 52. [Abstract] [PDF]
|
|
|
|
|
|
A. M. MAYOR, M. A. GOMEZ, D. M. FERNANDEZ, E. RIOS-OLIVARES, J. C. THOMAS, and R. F. HUNTER MORBIDITY AND MORTALITY PROFILE OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS WITH AND WITHOUT HEPATITIS C CO-INFECTION Am J Trop Med Hyg, February 1, 2006; 74(2): 239 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Goldberg, S. Himelhoch, J. Kreyenbuhl, F. B. Dickerson, A. Hackman, L. Juan Fang, C. H. Brown, K. A. Wohlheiter, and L. B. Dixon Predictors of HIV and Hepatitis Testing and Related Service Utilization Among Individuals With Serious Mental Illness Psychosomatics, December 1, 2005; 46(6): 573 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Seminari, G. Gentilini, L. Galli, H. Hasson, A. Danise, E. Carini, F. Dorigatti, A. Soldarini, A. Lazzarin, and A. Castagna Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients J. Antimicrob. Chemother., October 1, 2005; 56(4): 790 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Crook, S. Penumalee, B. Gavini, and K. Filippova Hepatitis C Is a Predictor of Poorer Renal Survival in Diabetic Patients Diabetes Care, September 1, 2005; 28(9): 2187 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Boston and J. C. Slish Management of HIV Infection in Persons Co-infected With Hepatitis Journal of Pharmacy Practice, August 1, 2005; 18(4): 295 - 309. [Abstract] [PDF]
|
|
|
|
|
|
I. Grau, R. Pallares, F. Tubau, M. H. Schulze, F. Llopis, D. Podzamczer, J. Linares, F. Gudiol, and for the Spanish Pneumococcal Infection Study Netwo Epidemiologic Changes in Bacteremic Pneumococcal Disease in Patients With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Therapy Arch Intern Med, July 11, 2005; 165(13): 1533 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rifai and D. L. Rosenstein Hepatitis C and Psychiatry Focus, April 1, 2005; 3(2): 194 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Kim, G. M. Lauer, K. Ouchi, M. M. Addo, M. Lucas, J. S. z. Wiesch, J. Timm, M. Boczanowski, J. E. Duncan, A. G. Wurcel, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1 Blood, February 1, 2005; 105(3): 1170 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Manns and H. Wedemeyer Treatment of Hepatitis C in HIV-Infected Patients: Significant Progress But Not the Final Step JAMA, December 15, 2004; 292(23): 2909 - 2913. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Pawlotsky Treating Hepatitis C in "Difficult-to-Treat" Patients N. Engl. J. Med., July 29, 2004; 351(5): 422 - 423. [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Abbott, J. R. Bucci, C. S. Matsumoto, S. J. Swanson, L. Y.C. Agodoa, K. C. Holtzmuller, D. F. Cruess, and T. G. Peters Hepatitis C and Renal Transplantation in the Era of Modern Immunosuppression J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2908 - 2918. [Abstract] [Full Text] [PDF]
|
|
Article
